Printer Friendly

Therapeutic candidate identified through Pharmacopeia collaboration enters development.

Pharmacopeia (Princeton, NJ), an innovator in the discovery and development of novel small molecule therapeutics, announced that a compound identified through the company's collaboration with Schering-Plough (Kenilworth, NJ) has been selected by Schering- Plough for preclinical development. Under terms of the companies' collaboration, this selection triggers a $1 million milestone payment to Pharmacopeia.

"This novel compound and its promising attributes were the basis for the extension of our collaboration with Schering-Plough last fall," stated Les Browne, Ph.D., President and Chief Executive Officer of Pharmacopeia. "Schering-Plough has been a valued collaborator for more than a decade, and we are proud of the extensive pipeline that this partnership has generated. We are hopeful that each of the four clinical and three preclinical programs currently in development from this collaboration will continue to advance in the coming years."

Schering-Plough is solely responsible for further development and commercialization of these candidates. However, Pharmacopeia is eligible to receive additional milestone payments related to the successful advancement of these programs, and will also receive royalties on sales of any therapeutic products resulting from these programs.

Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist for hypertension and diabetic kidney disease for which Phase 1 clinical trials are underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia's collaborative efforts have resulted in a portfolio that includes one partnered program currently in Phase 2 clinical trials targeting chronic obstructive pulmonary disease and four partnered programs in Phase 1 clinical trials targeting rheumatoid arthritis, oncology, metabolic and inflammatory diseases. Four additional partnered compounds are in preclinical development. Pharmacopeia's current strategic partnerships are with Cephalon, GlaxoSmithKline, Organon and Wyeth.


COPYRIGHT 2007 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Apr 1, 2007
Previous Article:Millennium discovers biomarkers potentially predictive of response to VELCADE.
Next Article:New European ARA infant formula patent strengthens Martek's intellectual property position.

Related Articles
Beyond Genomics and diaDexus enter cancer diagnostic research agreement.
Pharmacopeia and Organon to collaborate on identification.
Pharmacopeia achieves success in collaboration with Berlex.
Peregrine and Affitech to collborate on developing antibodies.
Pharmacopeia achieves research milestone in Celgene collaboration.
Pharmacopeia forms new research collaboration with Schering Plough.
Pharmacopeia collaborates with Schering-Plough on respiratory drug.
Pharmacopeia and Biovitrum collaboration advances towards development.
Pharmacopeia forms alliance with Cephalon to develop therapeutic products.
Organon and Pharmacopeia enter into discovery, development and commercialization alliance.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters